What is the difference between the molecule tirzepatide and the brands?
Tirzepatide is the name of the molecule — a 39-amino-acid synthetic peptide that acts as a dual agonist of the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. Eli Lilly developed the molecule and holds the patents.
Eli Lilly brought tirzepatide to market under two distinct brand names, for two different FDA-approved indications:
- Mounjaro — FDA-approved in May 2022 for the treatment of type 2 diabetes in adults, as an adjunct to diet and exercise.
- Zepbound— FDA-approved in November 2023 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity.
Same molecule. Same manufacturer. Different approved indications. Different brand names. Different pricing tiers in some pharmacy systems.
How does tirzepatide work?
Tirzepatide’s dual mechanism sets it apart from GLP-1-only agonists like semaglutide. It activates both:
- GLP-1 receptors: Slows gastric emptying, reduces appetite, promotes satiety, and stimulates glucose-dependent insulin release.
- GIP receptors: Modulates both insulin and glucagon secretion in a glucose-dependent manner; also has direct effects on adipose tissue metabolism and may amplify GLP-1-driven satiety signaling.
The dual-receptor approach is thought to contribute to the weight management outcomes observed in the SURMOUNT trial series, which reported greater average weight reductions than those seen in GLP-1-only agent trials at comparable durations.
It is important to note that individual results vary. No outcome can be guaranteed. Tirzepatide is a prescription medication requiring clinician evaluation, not an over-the-counter supplement.
Zepbound, Mounjaro, and compounded tirzepatide all share one molecule — but three different regulatory categories, never interchangeable on a label.
What is compounded tirzepatide, and how is it different from Zepbound?
Compounded tirzepatide is a third category, separate from both Mounjaro and Zepbound. It is prepared by licensed 503A compounding pharmacies from bulk tirzepatide active pharmaceutical ingredient (API) and dispensed under a licensed clinician’s prescription.
Compounded tirzepatide is not an FDA-approved drug. It does not carry the Mounjaro or Zepbound label. PepScribe works exclusively with licensed 503A compounding pharmacies in the United States — no hidden overseas supply chain. Every compounded formulation is prepared domestically under state board of pharmacy oversight.
During the documented shortage of branded tirzepatide (Mounjaro and Zepbound), the FDA has permitted licensed 503A compounding pharmacies to prepare compounded tirzepatide under specific conditions. The regulatory landscape for compounded tirzepatide continues to evolve and is subject to FDA enforcement discretion; a clinician can advise on current availability when you complete your intake.
How does Zepbound compare to compounded tirzepatide?
Zepbound is an FDA-approved branded drug; compounded tirzepatide is a separately regulated category. Key differences:
| Factor | Zepbound (branded) | Compounded tirzepatide |
|---|---|---|
| Regulatory status | FDA-approved drug | Not FDA-approved; regulated as compounded medication |
| Manufacturer | Eli Lilly (GMP facility) | Licensed 503A compounding pharmacy (USA) |
| Insurance coverage | May be covered (varies by plan) | Generally not covered; out-of-pocket |
| List price without insurance | Higher (list price $1,000+/month) | Substantially lower |
| Additives | Tirzepatide only | May include B12 or other additions (varies by pharmacy) |
Frequently asked questions
Is Zepbound the same as tirzepatide?
Zepbound contains tirzepatide as its active ingredient, but Zepbound is a specific branded product manufactured by Eli Lilly, FDA-approved for chronic weight management. Tirzepatide also exists under the brand name Mounjaro, which is FDA-approved for type 2 diabetes. So "tirzepatide" refers to the molecule; "Zepbound" and "Mounjaro" are the specific branded products containing that molecule, each with a different approved indication.
What is the difference between Zepbound and Mounjaro?
Both are the same molecule (tirzepatide) made by Eli Lilly. Mounjaro is FDA-approved for the treatment of type 2 diabetes. Zepbound is FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. The dosing ranges overlap but Zepbound offers an additional lower maintenance dose option.
Is compounded tirzepatide the same as Zepbound?
No. Compounded tirzepatide is a compounded medication prepared by a licensed 503A compounding pharmacy under a clinician's prescription. It is not manufactured by Eli Lilly, is not an FDA-approved drug, and should never be represented as equivalent to Zepbound or Mounjaro.
How does tirzepatide work for weight management?
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. This dual action slows gastric emptying, reduces appetite, and modulates insulin and glucagon secretion. The dual-receptor mechanism may contribute to the weight management outcomes observed in clinical trials compared to GLP-1-only agonists.
Can I get compounded tirzepatide instead of Zepbound?
During the documented shortage of branded tirzepatide products, licensed 503A compounding pharmacies have been permitted to prepare compounded tirzepatide under a clinician's prescription. A clinician can review your eligibility and, if appropriate, prescribe compounded tirzepatide from a licensed 503A pharmacy.
Does Zepbound require a prescription?
Yes. Zepbound is a prescription medication. It must be prescribed by a licensed clinician based on a clinical evaluation. The same applies to compounded tirzepatide — a valid prescription from a licensed prescriber is required.